Topic 377: Symptom Management and Intervention Roadmaps (STaIRS) (Moonshot)

许多不良症状在癌症护理中被忽视，导致1-3的机会错失 干预；导致治疗依从性差，可避免的住院，以及更糟糕的发病率和 生死存亡。国际移民组织建议将目前的症状范式从反应性转变为主动性， 个性化的、技术支持的症状护理模式，作为这一临床质量危机的解决方案。是这样的 主动护理模式减少了症状负担、急诊科使用，并提高了存活率。而当 商业上可用的症状监测和临床警报应用激增，它们缺乏 个性化的、可计算的算法，用于定制、基于证据的临床症状管理。这个 Carevive护理计划系统(CPS)是一个例外，它已经在商业上部署了症状监测 和评估工具、面向临床医生的内容以及用于患者自我管理的可计算算法 自2014年以来，通过专有规则引擎出现症状。这些资产，与国家统计局的内容和 Carevive广泛的专家顾问和客户网络将在第一阶段进入用户中心 临床医生疲劳评估与管理的计算机算法设计 便秘；集成临床数据以促进个性化、循证的症状护理，优于 现有的反应性和主动性症状护理方法。阶段I线框将是症状的基础 第二阶段的扩展、广泛的可用性和现场测试，最终是功效测试和全面 商业化。

Numerous adverse symptoms are under-detected in cancer care resulting1-3 in missed opportunities for intervention; leading to poor treatment adherence, avoidable hospitalizations, and worse morbidity and survival. The IOM proposed shaking up the current symptom paradigm from reactive to proactive, personalized, technology-enabled models of symptom care as a solution to this clinical quality crisis. Such proactive care models reduce symptom burden, emergency department use, and improve survival. While commercially-available symptom monitoring and clinical alerting applications proliferate, they lack personalized, computable algorithms for tailored, evidence-based clinical symptom management. The Carevive Care Planning System (CPS) is an exception, having commercially deployed symptom monitoring and assessment tools, clinician-facing content, and computable algorithms for patient self-management of symptoms since 2014, via a proprietary rules engine. These assets, combined with ONS content and Carevive’s extensive network of expert advisors and clients, will be leveraged in Phase I into the usercentered design of computable algorithms for clinician assessment and management of fatigue and constipation; integrating clinical data to facilitate personalized, evidence-based symptom care superior to existing reactive and proactive symptom care approaches. Phase I wireframes will be the basis for symptom expansion, extensive usability and field testing in Phase II, and ultimately efficacy testing and full-scale commercialization.